Yes. Cancer can cause seizures, either by growing directly into or pressing on the brain, by raising pressure inside the skull, by causing metabolic and electrolyte disturbances, or as a side effect of surgery, radiation, and certain chemotherapy drugs. Seizures occur in an estimated 20 to 40 percent of people with brain tumors and in 6 to 10 percent of all cancer patients at some point. In roughly 20 to 25 percent of adults with a newly diagnosed brain tumor, a seizure is the first sign anything is wrong. Whether a given cancer causes seizures depends on where it sits, how fast it grows, and what treatment the patient receives.
How cancer causes seizures: the irritated-cortex mechanism
A seizure is a burst of uncoordinated electrical firing from a group of neurons. For cancer to trigger one, something must lower the firing threshold of the cortex or strip away the inhibition that normally keeps neurons in check.
Direct tumor invasion does both. A tumor growing into the brain's gray matter disrupts the ion channels embedded in neuronal membranes and alters the balance of excitatory glutamate and inhibitory GABA signaling. Peritumoral tissue — the brain just outside the tumor edge — is often where seizures start, not the tumor core itself. That tissue shows elevated glutamate, reduced GABA receptors, and chronic inflammation driven by microglia.
Mass effect adds a second mechanism. A tumor that swells or blocks cerebrospinal fluid flow raises intracranial pressure. Stretching and distorting the cortex mechanically irritates it, and herniation compresses tissue. Both can provoke seizures, though raised pressure more commonly causes headache, vomiting, and altered consciousness.
Metabolic disruption is the third and most underappreciated route. Cancer cells consume glucose voraciously, and some tumors secrete hormones or trigger immune responses that disturb the brain's electrical environment.
In plain terms: cancer provokes seizures by electrically irritating brain tissue, squeezing it, or starving and poisoning the chemical bath the brain sits in.
Direct brain involvement: the largest single cause
Primary brain tumors and brain metastases account for the majority of cancer-related seizures. The numbers vary sharply by tumor type, location, and how the tumor grows.
| Tumor type | Seizure rate at diagnosis or during course | Usual driver |
|---|---|---|
| Low-grade glioma (grade 2) | 60 to 85 percent | Slow infiltration of cortex, high glutamate |
| Glioblastoma (grade 4) | 20 to 40 percent | Rapid growth, edema, mass effect |
| Meningioma (skull-base or convexity) | 20 to 50 percent | Cortical compression, dural irritation |
| Brain metastasis (lung, breast, melanoma) | 20 to 35 percent | Edema, peritumoral glutamate |
| Primary CNS lymphoma | 10 to 20 percent | Deep location, less cortical contact |
| Pituitary adenoma | Under 5 percent | Seizures rare unless it invades the cortex |
Low-grade gliomas stand out: the slower and more infiltrative the tumor, the higher the seizure risk, because those tumors sit in the cortex for years and rewire surrounding tissue. A fast-growing glioblastoma can destroy cortex so quickly that it produces fewer seizures relative to its size.
Location matters as much as biology. Tumors in the frontal, temporal, and parietal lobes are far more epileptogenic than those in the cerebellum or brainstem, because those lobes house the cortex and the temporal-limbic circuits where seizures most easily start. A small frontal metastasis can cause more seizures than a large cerebellar one.
Systemic cancers that cause seizures without touching the brain
Not every cancer-related seizure involves a tumor in the skull. Systemic cancers trigger seizures through metabolic and immune routes, and these cases are frequently misattributed.
Paraneoplastic syndromes are the clearest example. Some cancers — small-cell lung cancer, ovarian cancer, breast cancer, Hodgkin lymphoma — provoke an immune response that attacks the brain. The resulting limbic encephalitis or cerebellar degeneration causes seizures in a large share of affected patients. Antibodies like anti-Hu and anti-NMDA receptor antibodies are the common culprits. Seizures here can appear months before the cancer itself is diagnosed, which is why new adult-onset seizures in a smoker over 50 should prompt lung imaging.
Metabolic causes are more common still. Cancer can produce:
- Hyponatremia (low sodium) from SIADH, seen in small-cell lung cancer and others, which lowers the seizure threshold when sodium falls below roughly 120 to 125 mEq/L
- Hypoglycemia from insulin-secreting tumors or from liver failure, a well-known seizure trigger
- Hypercalcemia from bone metastases or parathyroid-related tumors, which can cause confusion and seizures
- Uremia or hepatic encephalopathy when cancer compromises kidney or liver function
Chemotherapy and supportive drugs contribute their own share. Some agents — including high-dose methotrexate, ifosfamide, and certain targeted therapies — carry seizure as a known neurotoxicity. Immunotherapy with checkpoint inhibitors can trigger autoimmune encephalitis, adding a newer and growing category of cancer-related seizures.
The timeline: when seizures appear across the cancer course
Timing is clinically useful because it points to the mechanism at work. A seizure that appears before diagnosis usually reflects the tumor itself. One that appears weeks after surgery may reflect edema or a postoperative complication. One that begins on a new drug points to that drug.
| When the seizure occurs | Likely mechanism | Typical workup |
|---|---|---|
| Before any cancer diagnosis | Tumor irritating cortex; metabolic disturbance | Brain MRI with contrast, electrolytes, glucose, EEG |
| Within 1 to 7 days of diagnosis | Tumor edema, raised intracranial pressure | Repeat imaging, steroids if edema is suspected |
| Within 30 days after brain surgery | Postoperative edema, hemorrhage, incomplete resection | Postoperative MRI, antiepileptic review |
| During radiation (weeks 2 to 6) | Radiation-induced edema, acute toxicity | MRI, steroid adjustment |
| 1 to 6 months after radiation | Radiation necrosis mimicking tumor growth | MRI with perfusion imaging, PET |
| During chemotherapy | Drug neurotoxicity, electrolyte shifts | Drug review, labs, EEG |
| Months to years after remission | Late recurrence, radiation necrosis, paraneoplastic process | Surveillance MRI, antibody panel |
Roughly one in five adults with a newly diagnosed brain tumor presents with a seizure as the first symptom, and about half of those have no prior neurological complaint. That statistic alone justifies treating new adult-onset seizures as a possible cancer signal.
Brain tumor versus non-tumor causes: a comparison
Patients and clinicians both ask how a cancer-related seizure differs from one caused by something else. The table below compares the main alternatives.
| Feature | Cancer-related seizure | Epilepsy (non-tumor) | Metabolic seizure | Post-stroke seizure |
|---|---|---|---|---|
| Usual age at onset | Any adult age; peak 45 to 65 | Often younger or with prior history | Any age; often elderly | Over 60 |
| Typical first clue | Focal weakness, headache, personality change | Seizure alone, often no deficit | Confusion, dehydration, new drug | Prior stroke or vascular risk |
| Brain imaging | Mass lesion or enhancement | Normal or hippocampal sclerosis | Normal | Old infarct |
| Key lab finding | May be normal | Normal | Low sodium, low glucose, high calcium | Normal |
| Recurrence risk without treatment | High (50 to 80 percent over 2 years) | Intermediate | Low once corrected | Moderate |
| First-line approach | Antiepileptic plus cancer treatment | Antiepileptic monotherapy | Correct the metabolic cause | Antiepileptic if indicated |
The single most useful differentiator is the MRI. A cancer-related seizure almost always comes with an identifiable lesion. A normal MRI in an adult with a first seizure makes cancer less likely, but does not exclude it, because some tumors and paraneoplastic processes are not visible on standard imaging.
What actually happens in the clinic: red flags and workup
The practical question a reader should be able to answer is what to do when a seizure could be cancer-related. Certain features should push anyone to seek urgent evaluation, and they are worth listing plainly.
Watch for these red-flag features:
- First seizure in an adult over 40 with no prior seizure history
- Focal onset — jerking of one arm, one side of the face, or a sensation that spreads
- New headache, vomiting, or double vision in the days before or after the seizure
- Known cancer of any type, especially lung, breast, or melanoma
- Confusion, personality change, or memory loss lasting beyond the seizure
If any of these apply, the workup begins with a brain MRI with contrast, electrolytes, glucose, calcium, and an EEG. A CT scan is used only when MRI is unavailable or in the emergency setting. Lumbar puncture is reserved for suspected carcinomatous meningitis or paraneoplastic syndromes once mass effect is ruled out.
Antiepileptic drug choice matters in cancer patients because many standard agents interact with chemotherapy through liver enzymes. Levetiracetam and lacosamide are favored in this population for that reason, per general neuro-oncology practice. Prophylactic antiepileptic treatment for patients with brain tumors but no seizures is not recommended, because the 2018 neuro-oncology guidance found no benefit in seizure prevention.
The non-obvious points: what the standard explanation misses
Three details rarely appear in brief explainers, and each changes how the topic should be understood.
First, seizures can precede a cancer diagnosis by years in paraneoplastic syndromes. Anti-NMDA receptor encephalitis, for instance, is associated with ovarian teratoma, and seizures may appear months before imaging reveals the tumor. Absence of a visible tumor on the first scan does not rule cancer out.
Second, the risk of seizures after brain tumor surgery depends heavily on whether the cortex was resected. A 2020 review of postoperative outcomes found seizure recurrence was significantly lower when the seizure focus was resected along with the tumor than when the tumor was removed while leaving the irritative cortex intact. This has changed surgical planning in some centers.
Third, corticosteroid use deserves a caution. Dexamethasone is routinely used to reduce tumor edema, and it works well, but it can also lower the seizure threshold in some patients and raise blood sugar, which itself is pro-convulsant. Steroid-induced seizures are a recognized, if uncommon, complication in brain tumor care.
What to actually do
If you or someone you know has cancer and a seizure occurs, the priorities are immediate and concrete.
Call emergency services for a seizure lasting more than five minutes, repeated seizures without recovery, or a seizure with trouble breathing. Do not restrain the person or put anything in the mouth.
For a first seizure without emergency features, arrange a same-week neurology evaluation with MRI and blood work ordered in advance so the visit is not delayed.
For a person already diagnosed with cancer, tell the oncology team about any new seizure immediately, because it may signal tumor progression, edema, or drug toxicity and may require imaging before the next treatment cycle.
For care partners, keep a written log of seizure timing, duration, and what the person was doing beforehand. That record often identifies the trigger and shapes treatment.
For anyone starting a new chemotherapy or immunotherapy drug, ask the oncology team whether seizure is a known side effect. The answer occasionally changes monitoring plans.
Limits of what science knows
The evidence linking cancer to seizures is strong at the level of association and mechanism, but several gaps remain. Most seizure-rate figures come from single-center series and vary widely by tumor type and era of treatment, so the percentages should be read as broad ranges rather than precise odds. The exact biochemical steps that convert an infiltrated cortex into an epileptic focus are still being mapped, and specific glutamate and GABA targets are hypotheses rather than established therapy.
Prevention remains unresolved. We know prophylactic antiepileptics do not prevent first seizures in brain tumor patients, but the best strategy for patients who have had one seizure is still debated, and the optimal duration of treatment is uncertain. Finally, the seizure risk from newer targeted therapies and immunotherapies is documented but not yet quantified precisely, which is a live research question as those drugs become more common. What is clear and well supported is the core answer: cancer can cause seizures through direct brain invasion, mass effect, metabolic disturbance, and treatment toxicity, and the specific mechanism determines how the seizure is treated.